论文部分内容阅读
目的观察多西他赛(希存)联合放疗对晚期鼻咽癌的近期疗效、3年生存率及急性不良反应。方法80例晚期鼻咽癌患者随机分为单纯放疗组(对照组)和放疗并用多西他赛放疗增敏组(治疗组),对其近期疗效、3年生存率及不良反应进行对比。两组放疗方法相同,治疗组于放疗前每周日加用多西他赛40 mg静滴,共7周。结果治疗组局部肿瘤消退时放疗剂量显著低于对照组(P<0.05),放疗结束时治疗组CR评价及3年生存率较对照组高,差异有显著性(P<0.05),治疗组急性不良反应较对照组增加,但差异无显著性(P>0.05)。结论多西他赛对晚期鼻咽癌放疗有增敏作用,可提高晚期鼻咽癌近期局部控制率及3年生存率,急性不良反应尚可耐受。
Objective To observe the short-term curative effect, 3-year survival rate and acute adverse reaction of docetaxel combined with radiotherapy on advanced nasopharyngeal carcinoma. Methods Eighty patients with advanced nasopharyngeal carcinoma were randomly divided into radiotherapy group (control group) and radiotherapy plus docetaxel radiosensitization group (treatment group). The curative effect, 3-year survival rate and adverse reactions were compared. Radiotherapy methods were the same in both groups, and the treatment group received docetaxel 40 mg intravenously every week before radiotherapy for 7 weeks. Results The dose of radiotherapy in treatment group was significantly lower than that in control group (P <0.05). At the end of radiotherapy, the CR evaluation and 3-year survival rate in treatment group were significantly higher than those in control group (P <0.05) Adverse reactions increased compared with the control group, but the difference was not significant (P> 0.05). Conclusion Docetaxel can sensitize the radiotherapy of advanced nasopharyngeal carcinoma and improve the recent local control rate and 3-year survival rate of advanced nasopharyngeal carcinoma. The acute adverse reaction is tolerable.